Skip to main content
Clinical Trials/NCT02275169
NCT02275169UnknownPhase 3

Follicle-stimulating Hormone Treatment for Infertile Male Patients With Non-obstructive Azoospermia: a Multicenter Randomized Clinical Trial

Azienda Sanitaria Locale Bari0 sites200 target enrollmentStarted: February 2015Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Enrollment
200
Primary Endpoint
Sperm retrieval rate (SRR)

Study Overview

Brief Summary

Aim of the study is to evaluate the effect of highly purified human follicle-stimulating hormone treatment on the chance of retrieving testicular sperm (sperm retrieval rate) from infertile male patients with non-obstructive azoospermia of unknown origin.

Detailed Description

Preliminary reports showed that hormonal treatment may improve the chance of retrieving viable testicular sperm from men with NOA, but no RCT are available in the field. This randomized placebo-controlled clinical trial sought to evaluate whether the testicular sperm retrieval rate could result higher in NOA patients treated with follicle-stimulating hormone compared to placebo-treated NOA subjects.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Azoospermia;
  • testis longitudinal axis less than 4.5 cm;
  • serum follicle-stimulating hormone greater than 7.6 IU/L

Exclusion Criteria

  • History of testicular biopsy,
  • malignancy,
  • varicocele,
  • hyperprolactinemia,
  • thyroid disfunction,
  • chemotherapy,
  • radiotherapy

Arms & Interventions

Treated

Experimental

Urofollitropin 150 IU ampoules three times a week for three months

Intervention: Urofollitropin (Drug)

Controls

Placebo Comparator

Placebo ampoules three times a week for three months

Intervention: Placebo (Other)

Outcomes

Primary Outcomes

Sperm retrieval rate (SRR)

Time Frame: three months

testicular sperm retrieval rate after three months of urofollitropin treatment

Secondary Outcomes

  • IVF pregnancy rate(three to six months)
  • IVF implantation rate(three to six months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ettore Caroppo

Dr

Azienda Sanitaria Locale Bari

Similar Trials